Instruction for medical use of Semavic®
Increased satiety
Insulin sensitivity
of cells
Insulin
Glucagon
β-cells’ function
Endogenous
glucose production
Nausea
Gastric emptying
Normalises
the lipid profile
Semavic® reduces the risk of major adverse cardiovascular events (1) Instruction for Medical Use of Semavic®
Semavic® decreases triglycerides and cholesterol concentrations (1) Instruction for Medical Use of Semavic®
Semavic® decreases systolic blood pressure (1) Instruction for Medical Use of Semavic®
Semavic® decreases blood glucose levels (plasma glucose and glycated haemoglobin (HbA1c)) in adult type 2 diabetes patients (1) Instruction for Medical Use of Semavic®
Semavic® suppresses appetite and reduces daily calorie intake by 18–35 % (1) Instruction for Medical Use of Semavic®
Semavic® helps lose weight, mainly through fat tissue loss (1) Instruction for Medical Use of Semavic®
Incretin receptor agonist medicinal products have broad beneficial effects on organ systems already under increased strain due to excess weight.
| Effect | Sibutramine-based conventional medicinal products |
Orlistat-based conventional medicinal products |
Semaglutide (Ozempic, Semavic®, etc.) |
|---|---|---|---|
| Weight loss |
4-6%
🛈
Study
Source link |
2-5 kg per course of treatment
🛈
Study
Source link |
10-15%
🛈
Study
Source link |
| Mode of action |
|
Reduces fat absorption from food → decreases caloric value per day |
|
| Heart and vessels |
Increased cardiovascular risks
Increased BP
Increased HR
🛈
Study
Source link |
- |
Normalisation of BP and HR Mitigating cardio vascular risks 🛈
Инструкция к препарату Семавик®
Source link |
| Appetite | Decreased appetite | - | Decreased appetite |
| Nervous system |
Increased nervousness 🛈
Инструкция к препаратам, содержащим сибутрамин
|
- |
Neuroprotection
🛈
Study
Source link |
| Kidneys |
Possible negative effect
🛈
Инструкция к препаратам, содержащим сибутрамин
|
- |
Protective effect
🛈
Study
Source link |
|
Sibutramine-based conventional medicinal products |
|
|---|---|
| Weight loss |
4-6%
ℹ
Study
Source link |
| Mode of action |
|
| Heart and vessels |
Increased cardiovascular risks
Increased BP
Increased HR
ℹ
Study
Source link |
| Appetite | Decreased appetite |
| Nervous system |
Increased nervousness ℹ
Инструкция к препаратам, содержащим сибутрамин
|
| Kidneys |
Possible negative effect ℹ
Инструкция к препаратам, содержащим сибутрамин
|
|
Orlistat-based conventional medicinal products |
|
|---|---|
| Weight loss |
2-5 kg per course of treatment ℹ
Study
Source link |
| Mode of action | Reduces fat absorption from food → decreases caloric value per day |
| Heart and vessels | - |
| Appetite | - |
| Nervous system | - |
| Kidneys | - |
|
Semaglutide (Ozempic, Semavic®, etc.) |
|
|---|---|
| Weight loss |
10-15%
ℹ
Study
Source link |
| Mode of action |
|
| Heart and vessels |
Normalisation of BP and HR Mitigating cardio vascular risks ℹ
Инструкция к препарату Семавик®
Source link |
| Appetite | Decreased appetite |
| Nervous system |
Neuroprotection
ℹ
Study
Source link |
| Kidneys |
Protective effect ℹ
Study
Source link |
| Name | Manufacturer | Gauge (G) | Length (mm) |
|---|---|---|---|
| Verifine | - | 29, 30, 31, 32 | 4, 5, 6, 8, 12 |
| Dexfine | IME-DC, Germany | 31, 32 | 4, 5, 6 |
| WellFine | Korea | 31, 32, 34 | 4, 5, 6, 8 |
| Insupen | Artsana S.P.A. | 30, 31, 32 | 4, 5, 6, 8 |
| Micro Fine | Becton Dickinson | 30, 31, 32 | 4, 5, 8, 12.7 |
| SFM needles | - | 29, 30, 31, 32 | 4, 5, 6, 8, 12.7 |
| Novo-Fine | Novo Nordisk | 30, 31 | 6, 8 |
| Droplet | HTL-Strefa. Inc. | 29 | 12 |
| Penfine | Ypsomed | 29, 31 | 6, 8, 10, 12 |
1.Instruction for Medical Use of Semavic®
2.Campbell JE, DJ Drucker. Cell Metab 2013;17:819–37.
3.Marso SP, et al. N Engl J Med 2016;375:311–22.
4.Ryan D, Acosta A. Obesity 2015;23:1119–29.
5.Hogan AE, et al. Diabetologia 2014;57:781–4.
6.Baggio LL, Drucker DJ. J Clin Invest 2014;124:4223–6.
7.Bagger JI, et al. Clin Endocrinol Metab 2015;100:4541–52.
8.Flint A, et al. J Clin Invest 1998;101:515–20.
9.Blundell J, et al. Oral Presentation 23-OR at the 76th Scientific Sessions of the American Diabetes Association, 10–14 June 2016, New Orleans, Louisiana, USA.
10.Tong J, D'Alessio D. Diabetes 2014;63:407–9.
11.Armstrong MJ, et al. J Hepatol 2016;64:399–408.
12.Armstrong MJ, et al. Lancet 2016;387:679–90.
13.Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375:1834-1844 (SUSTAIN 6).